User profiles for Brady Sillman
 | Brady Sillman, PhDInstructor, Department of Pharmacology and Experimental Neuroscience Verified email at unmc.edu Cited by 818 |
[HTML][HTML] Creation of a long-acting nanoformulated dolutegravir
Potent antiretroviral activities and a barrier to viral resistance characterize the human
immunodeficiency virus type one (HIV-1) integrase strand transfer inhibitor dolutegravir (DTG). …
immunodeficiency virus type one (HIV-1) integrase strand transfer inhibitor dolutegravir (DTG). …
[HTML][HTML] Sequential LASER ART and CRISPR treatments eliminate HIV-1 in a subset of infected humanized mice
…, M Donadoni, JA Robinson, B Sillman… - Nature …, 2019 - nature.com
Elimination of HIV-1 requires clearance and removal of integrated proviral DNA from infected
cells and tissues. Here, sequential long-acting slow-effective release antiviral therapy (…
cells and tissues. Here, sequential long-acting slow-effective release antiviral therapy (…
[HTML][HTML] Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation
Ultra-long-acting integrase strand transfer inhibitors were created by screening a library of
monomeric and dimeric dolutegravir (DTG) prodrug nanoformulations. This led to an 18-…
monomeric and dimeric dolutegravir (DTG) prodrug nanoformulations. This led to an 18-…
Pharmacokinetics of a long-acting nanoformulated dolutegravir prodrug in rhesus macaques
…, A Szlachetka, L Slack, B Sillman… - Antimicrobial agents …, 2018 - Am Soc Microbiol
A nanoformulated myristoylated dolutegravir prodrug (NMDTG) was prepared using good
laboratory practice protocols. Intramuscular injection of NMDTG (118 ± 8 mg/ml, 25.5 mg of …
laboratory practice protocols. Intramuscular injection of NMDTG (118 ± 8 mg/ml, 25.5 mg of …
A year-long extended release nanoformulated cabotegravir prodrug
Long-acting cabotegravir (CAB) extends antiretroviral drug administration from daily to
monthly. However, dosing volumes, injection site reactions and health-care oversight are …
monthly. However, dosing volumes, injection site reactions and health-care oversight are …
Long-acting slow effective release antiretroviral therapy
Introduction: Advances in long-acting antiretroviral therapy (ART) can revolutionize current
HIV/AIDS treatments. We coined the term ‘long-acting slow effective release ART’ (LASER …
HIV/AIDS treatments. We coined the term ‘long-acting slow effective release ART’ (LASER …
Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection
Adherence to daily oral antiretroviral therapy (ART) is a barrier to both treatment and
prevention of human immunodeficiency virus (HIV) infection. To overcome limitations of life-long …
prevention of human immunodeficiency virus (HIV) infection. To overcome limitations of life-long …
[HTML][HTML] Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs
Long-acting anti-HIV products can substantively change the standard of care for patients with
HIV/AIDS. To this end, hydrophobic antiretroviral drugs (ARVs) were recently developed for …
HIV/AIDS. To this end, hydrophobic antiretroviral drugs (ARVs) were recently developed for …
Neuropathogenesis of human immunodeficiency virus infection
B Sillman, C Woldstad, J Mcmillan… - Handbook of clinical …, 2018 - Elsevier
Human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND) remain
a common end-organ manifestation of viral infection. Subclinical and mild symptoms lead to …
a common end-organ manifestation of viral infection. Subclinical and mild symptoms lead to …
[HTML][HTML] Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir
A once every eight-week cabotegravir (CAB) long-acting parenteral is more effective than
daily oral emtricitabine and tenofovir disoproxil fumarate in preventing human …
daily oral emtricitabine and tenofovir disoproxil fumarate in preventing human …